Infectious Disease Testing - Research and Markets - RSS Feed

Infectious Disease Testing Market: US, Europe, Japan--Emerging Opportunities and Business Strategies

press@researchandmarkets.com — Fri, 20 Nov 2009 16:15:15 GMT

The infectious disease testing market is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers in the 21st century Among the main driving forces behind the growth of this dynamic market is continuous spread of AIDS, which remains...

Evidence-Based Infectious Diseases, 2nd Edition

press@researchandmarkets.com — Thu, 17 Sep 2009 08:48:48 GMT

The fully updated Second Edition of this case-led text provides an excellent introduction to evidence-based Clinical Practice for the major areas of infectious disease management The new edition takes on a brand new design and focus, making the book more accessible to junior doctors in infectious...

European Orphan Diseases Market

press@researchandmarkets.com — Mon, 06 Apr 2009 09:24:27 GMT

This research service deals with market drivers, restraints, market trends, competitive structure , revenues, technology trends and market attractiveness analysis of the European orphan diseases market Research Overview This Frost & Sullivan research service titled European Orphan Diseases Market...

Infectious Diseases Vaccine Market Overview: Key Companies & Strategies - In Times of Crisis, Big Pharma turns to Vaccines

press@researchandmarkets.com — Thu, 05 Feb 2009 12:44:32 GMT

Introduction

Long being regarded as an unattractive market, vaccines have re-emerged as successful growth driver for Big Pharma. The launch and rapid uptake of novel, high-price products such as Wyeths Prevnar or Merck & Cos Gardasil, along with the emergence of novel vaccine technologies and favourable legislation have brought vaccines back into the main focus of pharmaceutical and biotech companies.

Scope

- Market overview with current market assessment in terms of leading players, brands and geographies
- In-depth analyses of the leading 5 players portfolios, R&D pipelines, sales trends, geographic spread, licensing patterns and strategic outlook
- Discussion of key developments shaping the sector: new technologies, indications and geographies
- Snapshot profiles of second tier companies in the sector: strength in specialties

Highlights

With the exception of influenza, only two to three vaccine manufacturers compete for each disease. This lack of competition combined with public health requirements to guarantee a stable supply of vaccines has resulted in a recent upward shift of vaccine prices for specialty vaccines.

The most significant threat to the oligopoly of the Big 5 in the vaccines market comes from companies from emerging markets, which have large manufacturing capacities for biologics and are able to produce even complex substances like vaccines at low costs.

While vaccine sales have grown at a CAGR of 32% between 2004 and 2007 and shown an annual growth rate of 46% between 2006 and 2007, overall pharmaceutical sales have grown much more slowly, with both the 2004-2007 CAGR as well as the growth rate between 2006 and 2007 only reaching 8%.

Reasons to Purchase

- Get a comprehensive, insightful commercial overview of the vaccines market
- Learn about the strategies of the Big 5 players, their strengths, weaknesses, similarities and differences
- Gain insight into the future directions and growing strategic importance of vaccines for Big Pharma

Educational Review Manual in Infectious Disease

press@researchandmarkets.com — Mon, 12 Jan 2009 16:11:11 GMT

Originally created to assist US Infectious Disease fellows with their board exams, this manual is a comprehensive review of the subject by leading practitioners in the field. This manual also includes chapter specific Q&A sections.

These Educational Review Manuals ("ERM") are comprehensive yet concise reviews of medical specialties or subspecialties that are complimentary for all U.S. final-year residents, fellows, and physicians taking their board recertification exams.

Each manual is sponsored by a single pharmaceutical company with unrestricted educational funding. The gift of the manuals complies with all current OIG/HHS, PhRMA, and AMA physician gift guidelines.

Sponsors providing complimentary review manuals in 2008 include Boehringer Ingelheim, J&J/Merck, PriCara, (a unit of Ortho McNeil), Eisai, McNeil Consumer Healthcare, Merck & Co., Ortho McNeil Neurologics, Ortho Women’s Health & Urology, Shire, Takeda and Wyeth.

Each ERM consists of between 480 and 980 pages of text, with color and black-and-white images, graphic illustrations, and tables. Each chapter includes annotated questions and answers, and there is a section in each manual that provides tips on preparing for and taking the boards.

Please note: These books cannot be sold to clients in the U.S.

Study for Opportunities Assessment for Hepatitis B Therapeutics in India

press@researchandmarkets.com — Fri, 09 Jan 2009 11:58:02 GMT

This research service aims to provide an update on the epidemiology of Hepatitis B, current diagnostic and treatment practices, as well as market landscape in terms of major participants and future trends It covers the diabetes therapeutics market in India...

Study for Opportunities Assessment for Hepatitis B Therapeutics in Korea

press@researchandmarkets.com — Fri, 09 Jan 2009 11:51:01 GMT

This research service aims to provide an update on the epidemiology of hepatitis B, current diagnostic and treatment practices, as well as market landscape in terms of major participants and future trends It covers the diabetes therapeutics market in Korea...

Study for Opportunities Assessment for Hepatitis B Therapeutics in Taiwan

press@researchandmarkets.com — Fri, 09 Jan 2009 11:40:32 GMT

Infections and Wound Treatments

press@researchandmarkets.com — Tue, 15 Jan 2008 17:02:02 GMT

A recent ChangeWave healthcare survey focused on the treatment of infections and wounds – including Hospital Acquired Infections (HAIs) and Methicillin-Resistant Staphylococcus Aureus (MRSA) The survey was conducted October 11 -16, and 204 healthcare respondents working in a hospital or clinic...

Oxford Handbook of Genitourinary Medicine, HIV and AIDS, First Edition

press@researchandmarkets.com — Tue, 13 Mar 2007 15:05:59 GMT

- Provides a wealth of practical information on sexually transmitted diseases and the principles of providing services
- Includes evidence-based, practical information on the specialty, covering medico-legal, ethical, and procedural issues
- Includes a disease-orientated description of conditions both directly related and opportunistic, and their management, and data on special situations such as pregnancy
- Includes an extensive colour plate section

Genitourinary medicine (GUM) is an expanding specialty which is primarily related to the treatment and prevention of sexually transmitted infections (STIs). A number of GUM departments also offer other sexual health services such as contraception, sexual dysfunction and health promotion. Services are provided by multidisciplinary teams which include doctors, nurses, health advisers (who carry out partner notification and counselling), receptionists, laboratory staff and secretarial support.

The Handbook of Genitourinary Medicine HIV and AIDS provides practical, evidence-based information on the specialty, covering medico-legal, ethical, and procedural issues. The first section deals with routine management, special situations and clinical and laboratory processes. The second section covers genitourinary conditions in a disease-orientated style, including sexually transmitted diseases and other genitourinary problems. The third section on HIV provides a contemporary epidemiological overview of this infection, basic viral biology and pathogenesis, a disease-orientated description of conditions both directly related and opportunistic, and their management, and data on special situations such as pregnancy.

Readership: Aimed primarily at specialist doctors, trainees and nurses in genitourinary medicine and infectious diseases, this book will also appeal to gynaecologists, general practitioners, specialist nurses, and interested medical students.

Authors, editors, and contributors

- Edited by Richard Pattman, Consult

World Adult Infectious Diseases Vaccines Markets

press@researchandmarkets.com — Tue, 09 Jan 2007 11:36:21 GMT

New Innovations, Emerging Markets Propel Vaccine Industry

Though the global vaccines market accounts for approximately two percent of
the world pharmaceutical industry, the field has witnessed considerable
changes and positive growth over the past few years. The introduction of new
delivery systems, novel and combination vaccines, and improved vaccination
rates in emerging markets are expected to significantly impact the industry.

This Frost & Sullivan analysis provides a comprehensive evaluation of the
world adult infectious diseases vaccines markets. By offering a detailed analysis

of major segments and publicly-funded programs aimed at increasing
immunization rates, this study allows firms to take advantage of key
industry trends.

Nasal Inoculation Opens Doors to Lucrative Growth Opportunities

The most promising advancement for new delivery methods for influenza
vaccines is the development of a nasal delivery vaccine. One breakthrough
product is currently awaiting final approval by the FDA.This would be the first

nasal delivery flu vaccine and should prove profitable in markets where
patients’ fear of needles is a major challenge.

Nasal delivery strategies are being employed in an effort to boost
immunization rates. By focusing on the pediatric sector, one manufacturer is
attempting to create a new market opportunities for the vaccines, states the
author of this study.

Lack of Awareness Regarding the Health Risks of Hepatitis Hinders Market

Though hepatitis B is considered a third-world disease, a significant number of
European and North American adults contract the illness each year. A large

portion of the high-risk adult population is simply not aware of the potential

health problems associated with the disease or the fact that their lifestyle may
put them at increased risk.

This is especially true for sexually active males with multiple partners. Even
among the more knowledgeable high-risk groups, increased awareness does
not always tra

U.S. HIV/AIDS Therapeutic Markets

press@researchandmarkets.com — Tue, 21 Nov 2006 15:41:28 GMT

This report covers the markets for major HIV/AIDS drug therapies, including protease inhibitors (PIs), nucleoside reverse transcriptase inhibitors (NRTIs), and non-nucleoside reverse transcriptase inhibitors (NNRTIs). It also examines a range of emerging drugs and therapies. By evaluating challenges and presenting forecasts both by product and product type, this report offers its users a comprehensive guide to the HIV/AIDS drug markets. This report, which monitors industry changes and analyzes competitive strategies, can help your firm develop a winning plan of action. From Frost & Sullivan.

European HIV/AIDS Drug Markets

press@researchandmarkets.com — Tue, 21 Nov 2006 15:41:19 GMT

This Frost & Sullivan report analyzes the markets for a full range of HIV and AIDS pharmaceutical products, including protease inhibitors, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, anti-cytomegalovirus drugs and anitfungal drugs. The report examines industry challenges and provides recommendations for spurring growth. It also provides thorough analyses of the competitive field for each product segment in eight European regional markets. Key companies in the industry are profiled.

U.S. Infectious Diseases: Sexually Transmitted Disease Diagnostics Markets

press@researchandmarkets.com — Thu, 16 Nov 2006 14:41:46 GMT

Limited Awareness of Sexually Transmitted Diseases Stunts the Growth of a Dynamic Market

The asymptomatic nature of many sexually transmitted diseases (STDs) retards growth of the infectious disease diagnostic markets. Individuals generally undergo screening only if signs and symptoms of infection surface, which minimizes routine, voluntary screening. The Center for Disease Control estimates that nearly 3.9 million Americans have been infected with hepatitis C virus (HCV), and 25,000 individuals are diagnosed with hepatitis C annually. Yet, identification is prevented by the fact that nearly 80 percent of those infected have few if any signs or symptoms. Only the human immunodeficiency virus (HIV) has remained in the spotlight through educational initiatives, but other diseases have not had this kind of media attention that results in support and prevention.

This new research from Frost & Sullivan analyzes the U.S. Infectious Disease Diagnostics Markets, segmented as follows: HIV, HCV, Chlamydia/Gonorrhea, and the emerging market, Human Papilloma Virus diagnostics. The report provides strategic analysis and forecasts, discusses drivers and restraints, competitive environment, and industry trends.

Novel Technologies and Diagnostic Products Significantly Impact Healthcare and Create Niche Markets

The adaptation of existing technologies and the development of novel assays will drive the infectious disease diagnostics market in the future, says the analyst of this report. An increased level of response from the industry to deal with emerging infectious disease agents has created methods such as HIV and HCV genotyping. This has been cited as an important tool for recognizing the strains of virus that will be responsive to treatment.

The availability and efficacy of antiviral treatment, such as drug cocktails, has significantly prolonged the life expectancy of persons diagnosed with HIV. This has led to a growing population of patients that require routine viral mon

Latin American Rapid Test Markets for Infectious Diseases

press@researchandmarkets.com — Thu, 16 Nov 2006 14:41:45 GMT

This Frost & Sullivan research service entitled Latin American Rapid Tests Market for Infectious Diseases provides an overview on the Latin American region in terms of its stage of development in this market. It focuses on key market drivers and restraints shaping the current market and depicting the future trends together with a comprehensive quantitative analysis covering current market size, market share, and a 5 year market forecast for the three countries covered in the study: Brazil, Mexico and Argentina. In this research, Frost & Sullivans expert analysts thoroughly examine the following markets: Rapid tests application in the detection of HIV, Hepatitis C Virus, and Chagas for the three countries covered by this study.

Market Sector

Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this analysis:

- Rapid Tests for HIV detection
- Rapid Tests for HCV detection
- Rapid Tests for Chagas detection
Technologies
The following technologies are covered in this research:

- Inmunochromatography, DIA, HAI
- HAI, Immunoassays
- HAI
Market Overview
Rapid Test markets are undergoing dynamic development in many countries around the world. New techniques matching needs on sensibility and specificity of these tests are being marketed worldwide. Latin America is unfolding as a region of major untapped opportunities within this category. Both cultural and technological drivers are triggering new interest in Latin American healthcare distribution for simple diagnostics for fatal illness categories.
Latin America offers a diverse landscape in terms of market development for Rapid Tests for infectious diseases. While Mexico is relatively highly developed with respect to product distribution and technology for rapid test, Brazil and Argentina are in an earlier stage of product and market expansion and are likely to experience a significant inflow of new products and competitors in the next five years.

An Evaluation of Product Usage for Molecular Testing within Infectious Diseases - Norway, Denmark, Sweden, Finland, Belgium and Switzerland

press@researchandmarkets.com — Fri, 06 Aug 2004 10:16:18 GMT

The new report examines the reality of laboratories and hospitals in 6 European countries and provides you with following information: Molecular Tests - Description of laboratory landscape per country - the number of performed tests for 47 pathogens - which products, technologies and

An Evaluation of Product Usage for Molecular Testing within Infectious Diseases - Germany, France, Italy, UK & Spain

press@researchandmarkets.com — Fri, 06 Aug 2004 10:05:05 GMT

The new report examines the reality of laboratories and hospitals in 5 major European countries and provides you with following information: Molecular Tests - Description of laboratory landscape per country - the number of performed tests for 47 pathogens - which products, technologies and

An Evaluation of Product Usage for Molecular Testing within Infectious Diseases - Europe

press@researchandmarkets.com — Fri, 06 Aug 2004 09:52:19 GMT

The new report examines the reality of 221 laboratories and hospitals in 11 European countries and provides you with following information: Molecular Tests - Description of laboratory landscape per country - the number of performed tests for 47 pathogens - which products, technologies and